Britt J. Levy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Britt J. Levy has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Keith Emerson Linder
North Carolina State University
3 shared publications Lisa B. Mamo
Department of Clinical Sciences, College of Veterinary Medicine, NC State University, 1060 William Moore Drive, Raleigh, NC, 27607, USA
3 shared publications- Petra Bizikova
Department of Clinical Sciences, College of Veterinary Medicine North Carolina State University Raleigh North Carolina USA
3 shared publications - Ina Herrmann
Department of Clinical Sciences, College of Veterinary Medicine North Carolina State University Raleigh North Carolina USA
2 shared publications Amaliris Gonzalez
Department of Biology, Temple University, Philadelphia, Pennsylvania, USA
1 shared publicationAmanda T Parton Corr
Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
1 shared publication
Latest Publications
- 6 May 2020
- Published by Wiley in Veterinary Dermatology
- Vol. 31 (5) , 378-+
Detection of circulating anti‐keratinocyte autoantibodies in feline pemphigus foliaceus
Background: Circulating anti‐keratinocyte immunoglobulin (Ig)G targeting desmosomal proteins have been identified in people and dogs with pemphigus foliaceus (PF). By contrast, detection attempts in PF‐affected cats have been largely unsuccessful.Hypothesis/Objectives: To detect circulating anti‐keratinocyte autoantibodies in PF‐affected cats and determine their titres and tissue‐staining patterns.Animals: Thirty PF‐affected cats were compared to 11 specific‐pathogen free, 15 healthy and 31 allergic cats.Methods and materials: Sera were tested by indirect immunofluorescence on canine footpad and buccal mucosal substrates.Results: Circulating, anti‐keratinocyte IgG with a suprabasilar, web‐like (intercellular) pattern were detected in the majority of PF‐affected cats (23 of 30, 77%), some allergic cats (six of 31, 19%) and one healthy cat (7%). Both footpad epidermis and buccal mucosa were positive in the majority of seropositive PF‐affected cats (21 of 23, 91%), and in only one of six (17%) seropositive allergic cats. Staining was limited to the footpad in the remaining seropositive PF‐affected and allergic cats and one seropositive healthy cat. Reciprocal IgG titres were significantly higher in PF‐affected cats compared to controls (Dunn’s post‐test, P < 0.0001). Anti‐keratinocyte IgM, IgA or IgE were not detected in any sera.Conclusions and clinical importance: These results confirm the presence of circulating anti‐keratinocyte IgG in a majority of PF‐affected cats and in a small percentage of healthy and allergic cats. Although the molecular target and pathogenic nature of the antibodies remains unknown, the detection of positive immunostaining on buccal mucosal tissue, in addition to the footpad, suggests that the major target antigen of feline PF differs from that reported in dogs.
- 6 May 2020
- Published by Wiley in Veterinary Dermatology
- Vol. 31 (5) , 378-+
Detection of circulating anti‐keratinocyte autoantibodies in feline pemphigus foliaceus
Background: Circulating anti‐keratinocyte immunoglobulin (Ig)G targeting desmosomal proteins have been identified in people and dogs with pemphigus foliaceus (PF). By contrast, detection attempts in PF‐affected cats have been largely unsuccessful.Hypothesis/Objectives: To detect circulating anti‐keratinocyte autoantibodies in PF‐affected cats and determine their titres and tissue‐staining patterns.Animals: Thirty PF‐affected cats were compared to 11 specific‐pathogen free, 15 healthy and 31 allergic cats.Methods and materials: Sera were tested by indirect immunofluorescence on canine footpad and buccal mucosal substrates.Results: Circulating, anti‐keratinocyte IgG with a suprabasilar, web‐like (intercellular) pattern were detected in the majority of PF‐affected cats (23 of 30, 77%), some allergic cats (six of 31, 19%) and one healthy cat (7%). Both footpad epidermis and buccal mucosa were positive in the majority of seropositive PF‐affected cats (21 of 23, 91%), and in only one of six (17%) seropositive allergic cats. Staining was limited to the footpad in the remaining seropositive PF‐affected and allergic cats and one seropositive healthy cat. Reciprocal IgG titres were significantly higher in PF‐affected cats compared to controls (Dunn’s post‐test, P < 0.0001). Anti‐keratinocyte IgM, IgA or IgE were not detected in any sera.Conclusions and clinical importance: These results confirm the presence of circulating anti‐keratinocyte IgG in a majority of PF‐affected cats and in a small percentage of healthy and allergic cats. Although the molecular target and pathogenic nature of the antibodies remains unknown, the detection of positive immunostaining on buccal mucosal tissue, in addition to the footpad, suggests that the major target antigen of feline PF differs from that reported in dogs.
- 27 April 2020
- Published by Wiley in Veterinary Dermatology
- Vol. 31 (4) , 325-+
Cutaneous polyautoimmunity in two unrelated dogs: pemphigus foliaceus and generalized discoid lupus erythematosus
Background: Polyautoimmunity, the concurrent expression of two or more distinct autoimmune diseases (ADs) in a single individual, is a known phenomenon in humans and has been rarely reported in dogs. To the best of the authors’ knowledge, comorbid pemphigus foliaceus (PF) and generalized discoid lupus erythematosus (GDLE) has not been reported in dogs.Hypothesis/Objectives: To describe the clinical, histological and immunological features and treatment outcome of two unrelated dogs with comorbid PF and GDLE.Animals: One 10‐year‐old, spayed German shepherd dog and one 8‐year‐old, castrated American Staffordshire terrier presented for evaluation of a symmetrical, facial‐ and/or pedal‐dominant pustular dermatitis with concurrent, truncal scaly plaques.Methods: For each dog, clinicopathological characterization included physical examination, lesion cytological evaluation, bacterial culture and sensitivity testing, skin histopathological investigation and direct and indirect immunofluorescence testing. Additional diagnostic imaging and haematological testing was performed to exclude extracutaneous disease.Results: Both dogs exhibited lesions clinically and histologically compatible with PF and GDLE. Moreover, one dog exhibited generalized leucotrichia and chronic superficial keratitis. Remission was achieved with immunosuppressive dosages of prednisolone [high‐dose pulse (Case 1) or standard immunosuppressive dosage (Case 2)] and ciclosporin (5–6 mg/kg/day). Tissue‐bound antikeratinocyte immunoglobulin (Ig)G and IgM were detected in both dogs. A weak basement membrane zone deposit of C3 was seen in one dog. Circulating antikeratinocyte and anti‐desmocollin‐1 IgG were detected in one dog.Conclusions and clinical importance: Cutaneous polyautoimmunity can occur in the dog. Depending on the specific disease combinations, overlapping clinical features may present diagnostic and/or therapeutic challenges. Moreover, these cases should be monitored for development of additional cutaneous or extra‐cutaneous AD(s).
- 27 April 2020
- Published by Wiley in Veterinary Dermatology
- Vol. 31 (4) , 325-+
Cutaneous polyautoimmunity in two unrelated dogs: pemphigus foliaceus and generalized discoid lupus erythematosus
Background: Polyautoimmunity, the concurrent expression of two or more distinct autoimmune diseases (ADs) in a single individual, is a known phenomenon in humans and has been rarely reported in dogs. To the best of the authors’ knowledge, comorbid pemphigus foliaceus (PF) and generalized discoid lupus erythematosus (GDLE) has not been reported in dogs.Hypothesis/Objectives: To describe the clinical, histological and immunological features and treatment outcome of two unrelated dogs with comorbid PF and GDLE.Animals: One 10‐year‐old, spayed German shepherd dog and one 8‐year‐old, castrated American Staffordshire terrier presented for evaluation of a symmetrical, facial‐ and/or pedal‐dominant pustular dermatitis with concurrent, truncal scaly plaques.Methods: For each dog, clinicopathological characterization included physical examination, lesion cytological evaluation, bacterial culture and sensitivity testing, skin histopathological investigation and direct and indirect immunofluorescence testing. Additional diagnostic imaging and haematological testing was performed to exclude extracutaneous disease.Results: Both dogs exhibited lesions clinically and histologically compatible with PF and GDLE. Moreover, one dog exhibited generalized leucotrichia and chronic superficial keratitis. Remission was achieved with immunosuppressive dosages of prednisolone [high‐dose pulse (Case 1) or standard immunosuppressive dosage (Case 2)] and ciclosporin (5–6 mg/kg/day). Tissue‐bound antikeratinocyte immunoglobulin (Ig)G and IgM were detected in both dogs. A weak basement membrane zone deposit of C3 was seen in one dog. Circulating antikeratinocyte and anti‐desmocollin‐1 IgG were detected in one dog.Conclusions and clinical importance: Cutaneous polyautoimmunity can occur in the dog. Depending on the specific disease combinations, overlapping clinical features may present diagnostic and/or therapeutic challenges. Moreover, these cases should be monitored for development of additional cutaneous or extra‐cutaneous AD(s).
- 19 April 2020
- Published by Wiley in Veterinary Dermatology
- Vol. 31 (4) , 330-+
Rapid response of hyperkeratotic erythema multiforme to oclacitinib in two dogs
Background: Hyperkeratotic erythema multiforme (HKEM) is a clinically distinct dermatosis and poorly characterized syndrome, comprised of hyperkeratotic plaques with variable symmetry and apoptosis similar to “classic” erosive canine EM. Hyperkeratotic EM has a protracted clinical course and, although treatments with glucocorticoids, azathioprine and/or ciclosporin have been tried, rates of remission are low.Objectives: To describe successful treatment of HKEM in two dogs using oclacitinib.Animals: A 7‐year‐old, spayed Havanese dog (Case 1) and a 1‐year‐old, intact cryptorchid Dachshund dog (Case 2).Methods: Case characterization and clinical diagnoses were based on lesion character, surgical biopsy, cytological evaluation, culture, direct immunofluorescence (DIF) and expected responses to treatments.Results: Both cases exhibited multifocal, often symmetrical hyperkeratotic plaques with adherent scale. Histological findings revealed prominent epidermal hyperplasia, parakeratotic hyperkeratosis, lymphocytic dermatitis and transepidermal apoptosis with lymphocytic satellitosis. DIF revealed fine, patchy IgG, IgM and IgA basement membrane deposits (Case 2). Both dogs exhibited rapid improvement with oral oclacitinib (0.6–0.9 mg/kg twice daily) with a complete remission of clinical signs observed in 12 and seven weeks in cases 1 and 2, respectively.Conclusion and Clinical Importance: Oclacitinib could be considered as a fast‐acting and effective treatment option for HKEM in dogs.
- 19 April 2020
- Published by Wiley in Veterinary Dermatology
- Vol. 31 (4) , 330-+
Rapid response of hyperkeratotic erythema multiforme to oclacitinib in two dogs
Background: Hyperkeratotic erythema multiforme (HKEM) is a clinically distinct dermatosis and poorly characterized syndrome, comprised of hyperkeratotic plaques with variable symmetry and apoptosis similar to “classic” erosive canine EM. Hyperkeratotic EM has a protracted clinical course and, although treatments with glucocorticoids, azathioprine and/or ciclosporin have been tried, rates of remission are low.Objectives: To describe successful treatment of HKEM in two dogs using oclacitinib.Animals: A 7‐year‐old, spayed Havanese dog (Case 1) and a 1‐year‐old, intact cryptorchid Dachshund dog (Case 2).Methods: Case characterization and clinical diagnoses were based on lesion character, surgical biopsy, cytological evaluation, culture, direct immunofluorescence (DIF) and expected responses to treatments.Results: Both cases exhibited multifocal, often symmetrical hyperkeratotic plaques with adherent scale. Histological findings revealed prominent epidermal hyperplasia, parakeratotic hyperkeratosis, lymphocytic dermatitis and transepidermal apoptosis with lymphocytic satellitosis. DIF revealed fine, patchy IgG, IgM and IgA basement membrane deposits (Case 2). Both dogs exhibited rapid improvement with oral oclacitinib (0.6–0.9 mg/kg twice daily) with a complete remission of clinical signs observed in 12 and seven weeks in cases 1 and 2, respectively.Conclusion and Clinical Importance: Oclacitinib could be considered as a fast‐acting and effective treatment option for HKEM in dogs.
- 21 April 2019
- Published by Wiley in Veterinary Dermatology
- Vol. 30 (3) , 201-+
The role of oclacitinib in the management of ischaemic dermatopathy in four dogs
Background: Ischaemic dermatopathy represents a heterogenous and poorly‐characterized canine syndrome that is often refractory to conventional immunosuppression. Janus‐kinase inhibitors (JAKinibs) are used for the treatment of various human autoimmune diseases, including dermatomyositis. Oclacitinib is a generally well‐tolerated, veterinary‐approved, nonselective JAKinib that has therapeutic potential as an immunosuppressant.Hypothesis/Objectives: To describe four cases of treatment refractory juvenile‐onset ischaemic dermatopathy that rapidly and durably responded to oclacitinib administration.Animals: Four mixed‐breed dogs, three 9‐month‐old male littermates and one 6‐month‐old female, were presented for generalized patchy alopecia, scarring and ulcerative dermatitis. Microscopic skin lesions were consistent with a severe ischaemic dermatopathy.Methods and materials: A complete remission of skin lesions could not be achieved in any dog with glucocorticoids alone, nor when these were combined with adjuvant immunosuppressants. Oclacitinib treatment was then initiated at the dosage of 0.4‐0.7 mg/kg twice daily, along with a tapering regimen of oral prednisolone.Results: A full clinical remission was achieved within four weeks of starting this combination therapy, with prednisolone being stopped within eight weeks thereof. Remission was maintained in two dogs with lower doses or dosing frequencies of oclacitinib, whereas the two others required persistent twice daily administration of this JAKinib.Conclusions and clinical importance: Oclacitinib was a useful immunosuppressive adjuvant to oral glucocorticoids for the treatment of refractory or severe cases of ischaemic dermatopathy in these four dogs. Such observation warrants further studies of the safety, efficacy and mechanism of action of oclacitinib as an immunosuppressant.
- 21 April 2019
- Published by Wiley in Veterinary Dermatology
- Vol. 30 (3) , 201-+
The role of oclacitinib in the management of ischaemic dermatopathy in four dogs
Background: Ischaemic dermatopathy represents a heterogenous and poorly‐characterized canine syndrome that is often refractory to conventional immunosuppression. Janus‐kinase inhibitors (JAKinibs) are used for the treatment of various human autoimmune diseases, including dermatomyositis. Oclacitinib is a generally well‐tolerated, veterinary‐approved, nonselective JAKinib that has therapeutic potential as an immunosuppressant.Hypothesis/Objectives: To describe four cases of treatment refractory juvenile‐onset ischaemic dermatopathy that rapidly and durably responded to oclacitinib administration.Animals: Four mixed‐breed dogs, three 9‐month‐old male littermates and one 6‐month‐old female, were presented for generalized patchy alopecia, scarring and ulcerative dermatitis. Microscopic skin lesions were consistent with a severe ischaemic dermatopathy.Methods and materials: A complete remission of skin lesions could not be achieved in any dog with glucocorticoids alone, nor when these were combined with adjuvant immunosuppressants. Oclacitinib treatment was then initiated at the dosage of 0.4‐0.7 mg/kg twice daily, along with a tapering regimen of oral prednisolone.Results: A full clinical remission was achieved within four weeks of starting this combination therapy, with prednisolone being stopped within eight weeks thereof. Remission was maintained in two dogs with lower doses or dosing frequencies of oclacitinib, whereas the two others required persistent twice daily administration of this JAKinib.Conclusions and clinical importance: Oclacitinib was a useful immunosuppressive adjuvant to oral glucocorticoids for the treatment of refractory or severe cases of ischaemic dermatopathy in these four dogs. Such observation warrants further studies of the safety, efficacy and mechanism of action of oclacitinib as an immunosuppressant.
- 1 March 2018
- Published by Wiley in Veterinary Dermatology
- Vol. 29 (3) , 243-e90
A preliminary study of serum IgE against cross‐reactive carbohydrate determinants (CCD) in client‐owned atopic dogs
Background: Cross‐reactive carbohydrate determinants (CCD) are defined carbohydrate portions of glycoprotein cell surface molecules common to many plant and insect species. Mammalian species recognize CCD as foreign antigens and can mount humoral immune responses against them. Approximately 20–37% of grass and venom allergic people possess circulating IgE against CCD; these antibodies are generally considered clinically irrelevant. Anti‐CCD IgE is, however, recognized as a cause of false positive, clinically incongruent serum allergen test results in people; this phenomenon has not been investigated in animals.Objective: To determine if anti‐CCD IgE could be detected in sera of client‐owned atopic dogs and how frequently it is found.Animals: Sera from 38 dogs with a clinical diagnosis of atopic dermatitis and prior serological evidence of IgE antibodies, defined as a positive result to at least one mite and pollen (of any type).Methods: Sera were analysed for IgE against CCD and environmental allergens with a commercially available multiplex enzyme‐labelled allergen‐specific IgE assay.Results: Anti‐CCD IgE was detected in nine of 38 (24%) of atopic dog sera. As with their human counterparts, all dogs with anti‐CCD IgE had strong serological reactivity to grass pollens.Conclusions and Clinical Importance: Anti‐CCD IgE can confound serological allergen testing in people; the same might be true in dogs. Further studies are warranted to investigate the clinical implications of anti‐CCD IgE in dogs, including the potential for these antibodies to affect serum allergen‐specific IgE assays used for clinical diagnosis, and whether they are relevant to clinical disease.
- 1 March 2018
- Published by Wiley in Veterinary Dermatology
- Vol. 29 (3) , 243-e90
A preliminary study of serum IgE against cross‐reactive carbohydrate determinants (CCD) in client‐owned atopic dogs
Background: Cross‐reactive carbohydrate determinants (CCD) are defined carbohydrate portions of glycoprotein cell surface molecules common to many plant and insect species. Mammalian species recognize CCD as foreign antigens and can mount humoral immune responses against them. Approximately 20–37% of grass and venom allergic people possess circulating IgE against CCD; these antibodies are generally considered clinically irrelevant. Anti‐CCD IgE is, however, recognized as a cause of false positive, clinically incongruent serum allergen test results in people; this phenomenon has not been investigated in animals.Objective: To determine if anti‐CCD IgE could be detected in sera of client‐owned atopic dogs and how frequently it is found.Animals: Sera from 38 dogs with a clinical diagnosis of atopic dermatitis and prior serological evidence of IgE antibodies, defined as a positive result to at least one mite and pollen (of any type).Methods: Sera were analysed for IgE against CCD and environmental allergens with a commercially available multiplex enzyme‐labelled allergen‐specific IgE assay.Results: Anti‐CCD IgE was detected in nine of 38 (24%) of atopic dog sera. As with their human counterparts, all dogs with anti‐CCD IgE had strong serological reactivity to grass pollens.Conclusions and Clinical Importance: Anti‐CCD IgE can confound serological allergen testing in people; the same might be true in dogs. Further studies are warranted to investigate the clinical implications of anti‐CCD IgE in dogs, including the potential for these antibodies to affect serum allergen‐specific IgE assays used for clinical diagnosis, and whether they are relevant to clinical disease.
- 18 September 2017
- Published by Wiley in Veterinary Dermatology
- Vol. 29 (1) , 78-e31
Multimodal treatment of a dog with disseminated cutaneous viral papillomatosis
Canine papillomaviruses (CPVs) are associated with varied cutaneous manifestations. Spontaneous resolution typically occurs within one to 12 months. This case report describes multimodal treatment of a dog with severe disseminated papillomatosis. An eight-month-old, female spayed, mixed breed dog was presented with a two month history of rapidly progressing papillomatosis and lack of response to oral azithromycin therapy. The dog was severely pruritic and malodorous; the weight and growth of lesions had progressed to affect the dog's gait and vision, and led to decreased quality of life. The dog was treated with substantial surgical debulking of lesions, followed by daily topical 5% imiquimod cream applied to nonexcisable lesions, and received five doses of an experimental recombinant CPV2 L1 vaccine every 14 days for 10 weeks. At the end of the 10 weeks, two lesions remained and were excised. No additional treatment was needed and 10 months post-treatment the dog was lesion free. New therapies need to be developed and assessed, in controlled treatment trials, to determine the efficacy of single modality therapeutic interventions for severe, persistent canine cutaneous papillomatosis. 犬乳头状瘤病毒(CPV)可引发多种皮肤症状。通常在1到12个月内可以自愈。本病例报告描述了一例犬严重乳头状瘤病的多种方式治疗。 只八月龄杂种绝育母犬,该犬的乳头状瘤在两个月内快速发展,口服阿奇霉素治疗无效。犬严重瘙痒和恶臭;病变重量发展到影响犬的步态和视力,导致生活质量下降。该犬进行了大量手术切除病变,随后每日局部使用5%的咪喹莫特乳膏,涂抹于不能切除的病变部分,并且每14天接受5次试验性重组CPV2 L1疫苗注射,持续10周。在10周结束时,两个遗留病灶被切除。不需要额外的治疗,治疗后10个月时犬无病变。 在对照治疗试验中,需要开发和评估新的疗法,以确定单一形式治疗干预,对严重持续性犬皮肤乳头状瘤病的疗效。 Les papillomavirus canins (CPVs) sont associés à des manifestations cutanées variées. Une résolution spontanée se produit classiquement en un à 12 mois. Ce cas clinique décrit le traitement multimodal d'un chien présentant une papillomatose disséminée sévère. Une chienne croisée stérilisée de huit mois est présentée avec une papillomatose évoluant rapidement depuis deux mois et une absence de réponse à un traitement oral d'azithromycine. Le chien était sévèrement prurigineux et nauséabond ; les lésions se sont développées au point d'affecter la démarche et la vision et ont entrainé une baisse de la qualité de vie. Le chien a été traité par débridement chirurgical des lésions, puis par une application topique sur les lésions non opérables de crème imiquimod 5% et a reçu cinq doses d'un vaccin expérimental recombinant CPV2 L1 tous les 14 jours pendant 10 semaines. A la fin des 10 semaines, deux lésions persistaient et ont été retirées. Aucun traitement supplémentaire n'a été nécessaire et 10 mois après traitement, le chien était alésionnel. De nouveaux traitements doivent être développés et évalués dans des essais cliniques contrôlés pour déterminer l'efficacité de traitement unimodal pour les papillomatoses cutanées canines sévères et persistantes. Die caninen Papillomviren (CPVs) treten mit unterschiedlichen Hautmanifestationen auf. Eine spontane Resolution erfolgt typischerweise nach einem bis 12 Monaten. Dieser Fallbericht beschreibt die multimodale Behandlung eines Hundes mit hochgradiger disseminierter Papillomatose. Eine acht Monate alte kastrierte Mischlingshündin wurde mit einer zwei monatigen Vorgeschichte einer sich rasch ausbreitenden Papillomatose und mangelnder Verbesserung auf Azithromyzin Therapie per os vorgestellt. Der Hund war hochgradig juckend und hatte einen schlechten Körpergeruch; das Gewicht und Wachstum der Hautveränderungen hatte sich derart entwickelt, dass der Gang und die Sicht des Hundes beeinträchtigt waren, was zu einer Verschlechterung der Lebensqualität führte. Bei diesem Hund wurden die Veränderungen chirurgisch massiv abgetragen, danach wurde 5%ige Imiquimod Creme auf die nichtoperablen Veränderungen aufgetragen und der Hund bekam fünf Dosen einer experimentellen rekombinanten CPV2 L1 Vakzine, die alle 14 Tage für 10 Wochen verabreicht wurde. Am Ende der 10 Wochen bestanden noch zwei Läsionen, die herausgeschnitten wurden. Es war keine zusätzliche Behandlung nötig und 10 Monate nach der Behandlung war der Hund ohne Läsionen. Es müssen neue Therapien in kontrollierten Therapiestudien entwickelt und evaluiert werden, um die Wirksamkeit einer einzelnen therapeutischen Intervention für eine hochgradige, persistierende canine cutane Papillomatose zu untersuchen. 犬乳頭腫ウィルス(CPV)は、様々な皮膚症状に関連する。一般的に、1〜12ヶ月以内に自然治癒する。この症例報告では、重症播種性乳頭腫症を伴う犬の多岐におよぶ治療を記載する。 8ヵ月齢の避妊雌の雑種犬が、2ヶ月におよぶ急性に進行し、経口アジスロマイシン治療に反応しない乳頭腫症を呈して来院した。犬は重度の掻痒と悪臭を呈していた。大きく拡大した病変が犬の歩行や視力に影響を与え、生活の質の低下につながっていた。犬は病変の減量手術を受け、切除できなかった病変に関しては5%イミキモドクリームの局所塗布を毎日実施した。また、実験的組換えCPV2 L1ワクチンを14日毎に計5回、10週間投与された。10週間後、残っていた2つの病変が切除された。犬は、治療10ヶ月後も追加治療の必要なく、病変の再発も認められてない。 重度の持続性犬皮膚乳頭腫症に対する新しい治療の開発及び、対照臨床治験による単一治療の有効性の評価が必要がある。 Os papilomavírus caninos (PVCs) são associados a diversas manifestações cutâneas. A resolução espontânea tipicamente ocorre dentro de um a 12 meses. Este relato de caso descreve o tratamento multimodal de um cão com papilomatose severa a disseminada. Uma cadela castrada, sem raça definida, de oito meses de idade foi apresentada com um histórico de dois meses de papilomatose de evolução rápida e ausência de resposta ao tratamento com azitromicina. A cadela apresentava prurido severo e mau odor; o tamanho e o peso das lesões progrediram até afetar a visão e a marcha do animal, levando a perda na qualidade de vida. A cadela foi tratada com debridamento cirúrgico substancial, seguido de terapia tópica com creme de imiquimod a 5%, aplicado sobre lesões não operáveis, e recebeu cinco doses de uma vacina PVC2 L1 recombinante a cada 14 dias, por 10 semanas. Ao final deste período, duas lesões permaneceram e foram removidas cirurgicamente. Nenhum tratamento adicional foi necessário e dez meses após o tratamento, o animal ainda permanecia livre de lesões. São necessários o desenvolvimento e a avaliação de novas terapias, em ensaios clínicos controlados, para determinar a eficácia de modalidades terapêuticas de monoterapia para a papilomatose cutânea canina severa e persistente. Los papilomavirus caninos (CPV) están asociados con diversas manifestaciones cutáneas. La resolución espontánea típicamente ocurre entre uno a 12 meses. Este caso describe el tratamiento multimodal de un perro con papilomatosis diseminada severa. Una perra de ocho meses de edad, esterilizada y mestizase se presentó con una historia de dos meses de papilomatosis progresando rápidamente y con falta de respuesta a la terapia con azitromicina oral. El perro tenía prurito severo y mal olor; el peso y el crecimiento de las lesiones había progresado para afectar la ambulación y la visión, causando un deterioro de la calidad de vida. Se realizó una importante extirpación parcial de las lesiones, seguido de tratamiento tópico con crema al 5% de imiquimod tópica aplicada a lesiones no extirpables y recibió cinco dosis de una vacuna recombinante experimental de CPV2 L1 cada 14 días durante 10 semanas. Al final de las 10 semanas, dos lesiones permanecieron y fueron extirpadas. No se necesitó tratamiento adicional y 10 meses después del tratamiento, el perro no presentaba lesiones. se deben desarrollar nuevas terapias de modalidad única y ser evaluadas en pruebas clínicas controladas para determinar su eficacia frente a la papilomatosis cutánea canina severa y persistente.
- 18 September 2017
- Published by Wiley in Veterinary Dermatology
- Vol. 29 (1) , 78-e31
Multimodal treatment of a dog with disseminated cutaneous viral papillomatosis
Canine papillomaviruses (CPVs) are associated with varied cutaneous manifestations. Spontaneous resolution typically occurs within one to 12 months. This case report describes multimodal treatment of a dog with severe disseminated papillomatosis. An eight-month-old, female spayed, mixed breed dog was presented with a two month history of rapidly progressing papillomatosis and lack of response to oral azithromycin therapy. The dog was severely pruritic and malodorous; the weight and growth of lesions had progressed to affect the dog's gait and vision, and led to decreased quality of life. The dog was treated with substantial surgical debulking of lesions, followed by daily topical 5% imiquimod cream applied to nonexcisable lesions, and received five doses of an experimental recombinant CPV2 L1 vaccine every 14 days for 10 weeks. At the end of the 10 weeks, two lesions remained and were excised. No additional treatment was needed and 10 months post-treatment the dog was lesion free. New therapies need to be developed and assessed, in controlled treatment trials, to determine the efficacy of single modality therapeutic interventions for severe, persistent canine cutaneous papillomatosis. 犬乳头状瘤病毒(CPV)可引发多种皮肤症状。通常在1到12个月内可以自愈。本病例报告描述了一例犬严重乳头状瘤病的多种方式治疗。 只八月龄杂种绝育母犬,该犬的乳头状瘤在两个月内快速发展,口服阿奇霉素治疗无效。犬严重瘙痒和恶臭;病变重量发展到影响犬的步态和视力,导致生活质量下降。该犬进行了大量手术切除病变,随后每日局部使用5%的咪喹莫特乳膏,涂抹于不能切除的病变部分,并且每14天接受5次试验性重组CPV2 L1疫苗注射,持续10周。在10周结束时,两个遗留病灶被切除。不需要额外的治疗,治疗后10个月时犬无病变。 在对照治疗试验中,需要开发和评估新的疗法,以确定单一形式治疗干预,对严重持续性犬皮肤乳头状瘤病的疗效。 Les papillomavirus canins (CPVs) sont associés à des manifestations cutanées variées. Une résolution spontanée se produit classiquement en un à 12 mois. Ce cas clinique décrit le traitement multimodal d'un chien présentant une papillomatose disséminée sévère. Une chienne croisée stérilisée de huit mois est présentée avec une papillomatose évoluant rapidement depuis deux mois et une absence de réponse à un traitement oral d'azithromycine. Le chien était sévèrement prurigineux et nauséabond ; les lésions se sont développées au point d'affecter la démarche et la vision et ont entrainé une baisse de la qualité de vie. Le chien a été traité par débridement chirurgical des lésions, puis par une application topique sur les lésions non opérables de crème imiquimod 5% et a reçu cinq doses d'un vaccin expérimental recombinant CPV2 L1 tous les 14 jours pendant 10 semaines. A la fin des 10 semaines, deux lésions persistaient et ont été retirées. Aucun traitement supplémentaire n'a été nécessaire et 10 mois après traitement, le chien était alésionnel. De nouveaux traitements doivent être développés et évalués dans des essais cliniques contrôlés pour déterminer l'efficacité de traitement unimodal pour les papillomatoses cutanées canines sévères et persistantes. Die caninen Papillomviren (CPVs) treten mit unterschiedlichen Hautmanifestationen auf. Eine spontane Resolution erfolgt typischerweise nach einem bis 12 Monaten. Dieser Fallbericht beschreibt die multimodale Behandlung eines Hundes mit hochgradiger disseminierter Papillomatose. Eine acht Monate alte kastrierte Mischlingshündin wurde mit einer zwei monatigen Vorgeschichte einer sich rasch ausbreitenden Papillomatose und mangelnder Verbesserung auf Azithromyzin Therapie per os vorgestellt. Der Hund war hochgradig juckend und hatte einen schlechten Körpergeruch; das Gewicht und Wachstum der Hautveränderungen hatte sich derart entwickelt, dass der Gang und die Sicht des Hundes beeinträchtigt waren, was zu einer Verschlechterung der Lebensqualität führte. Bei diesem Hund wurden die Veränderungen chirurgisch massiv abgetragen, danach wurde 5%ige Imiquimod Creme auf die nichtoperablen Veränderungen aufgetragen und der Hund bekam fünf Dosen einer experimentellen rekombinanten CPV2 L1 Vakzine, die alle 14 Tage für 10 Wochen verabreicht wurde. Am Ende der 10 Wochen bestanden noch zwei Läsionen, die herausgeschnitten wurden. Es war keine zusätzliche Behandlung nötig und 10 Monate nach der Behandlung war der Hund ohne Läsionen. Es müssen neue Therapien in kontrollierten Therapiestudien entwickelt und evaluiert werden, um die Wirksamkeit einer einzelnen therapeutischen Intervention für eine hochgradige, persistierende canine cutane Papillomatose zu untersuchen. 犬乳頭腫ウィルス(CPV)は、様々な皮膚症状に関連する。一般的に、1〜12ヶ月以内に自然治癒する。この症例報告では、重症播種性乳頭腫症を伴う犬の多岐におよぶ治療を記載する。 8ヵ月齢の避妊雌の雑種犬が、2ヶ月におよぶ急性に進行し、経口アジスロマイシン治療に反応しない乳頭腫症を呈して来院した。犬は重度の掻痒と悪臭を呈していた。大きく拡大した病変が犬の歩行や視力に影響を与え、生活の質の低下につながっていた。犬は病変の減量手術を受け、切除できなかった病変に関しては5%イミキモドクリームの局所塗布を毎日実施した。また、実験的組換えCPV2 L1ワクチンを14日毎に計5回、10週間投与された。10週間後、残っていた2つの病変が切除された。犬は、治療10ヶ月後も追加治療の必要なく、病変の再発も認められてない。 重度の持続性犬皮膚乳頭腫症に対する新しい治療の開発及び、対照臨床治験による単一治療の有効性の評価が必要がある。 Os papilomavírus caninos (PVCs) são associados a diversas manifestações cutâneas. A resolução espontânea tipicamente ocorre dentro de um a 12 meses. Este relato de caso descreve o tratamento multimodal de um cão com papilomatose severa a disseminada. Uma cadela castrada, sem raça definida, de oito meses de idade foi apresentada com um histórico de dois meses de papilomatose de evolução rápida e ausência de resposta ao tratamento com azitromicina. A cadela apresentava prurido severo e mau odor; o tamanho e o peso das lesões progrediram até afetar a visão e a marcha do animal, levando a perda na qualidade de vida. A cadela foi tratada com debridamento cirúrgico substancial, seguido de terapia tópica com creme de imiquimod a 5%, aplicado sobre lesões não operáveis, e recebeu cinco doses de uma vacina PVC2 L1 recombinante a cada 14 dias, por 10 semanas. Ao final deste período, duas lesões permaneceram e foram removidas cirurgicamente. Nenhum tratamento adicional foi necessário e dez meses após o tratamento, o animal ainda permanecia livre de lesões. São necessários o desenvolvimento e a avaliação de novas terapias, em ensaios clínicos controlados, para determinar a eficácia de modalidades terapêuticas de monoterapia para a papilomatose cutânea canina severa e persistente. Los papilomavirus caninos (CPV) están asociados con diversas manifestaciones cutáneas. La resolución espontánea típicamente ocurre entre uno a 12 meses. Este caso describe el tratamiento multimodal de un perro con papilomatosis diseminada severa. Una perra de ocho meses de edad, esterilizada y mestizase se presentó con una historia de dos meses de papilomatosis progresando rápidamente y con falta de respuesta a la terapia con azitromicina oral. El perro tenía prurito severo y mal olor; el peso y el crecimiento de las lesiones había progresado para afectar la ambulación y la visión, causando un deterioro de la calidad de vida. Se realizó una importante extirpación parcial de las lesiones, seguido de tratamiento tópico con crema al 5% de imiquimod tópica aplicada a lesiones no extirpables y recibió cinco dosis de una vacuna recombinante experimental de CPV2 L1 cada 14 días durante 10 semanas. Al final de las 10 semanas, dos lesiones permanecieron y fueron extirpadas. No se necesitó tratamiento adicional y 10 meses después del tratamiento, el perro no presentaba lesiones. se deben desarrollar nuevas terapias de modalidad única y ser evaluadas en pruebas clínicas controladas para determinar su eficacia frente a la papilomatosis cutánea canina severa y persistente.
- Open Access
- 1 June 2013
- Published by Elsevier in Molecular Therapy
- Vol. 21 (6) , 1131-1141
Transient Photoreceptor Deconstruction by CNTF Enhances rAAV-Mediated Cone Functional Rescue in Late Stage CNGB3-Achromatopsia
- 1 June 2013
- Published by Elsevier in Molecular Therapy
- Vol. 21 (6) , 1131-1141
Open AccessTransient Photoreceptor Deconstruction by CNTF Enhances rAAV-Mediated Cone Functional Rescue in Late Stage CNGB3-Achromatopsia